Synapse - Genitourinary Oncology Service

Results (5696)

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Schonhoft, J.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Jayaram, A.; Winquist, E.; Landers, M.; Wang, Y.; Allan, A. L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma

Meeting Abstract

Rosenberg, J. E.; Ballman, K. V.; Halabi, S.; Watt, C.; Hahn, O. M.; Steen, P. D.; Dreicer, R.; Flaig, T. W.; Stadler, W. M.; Sweeney, C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis

Meeting Abstract

Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R. E.; Bracarda, S.; Bedke, J.; De Giorgi, U.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations

Meeting Abstract

Reimers, M. A.; Abida, W.; Chou, J.; George, D. J.; Heath, E. I.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; Choi, J. E.; Feng, F. Y.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors

Meeting Abstract

Razavi, P.; dos Anjos, C. H.; Brown, D. N.; Qing, L.; Ping, C.; Herbert, J.; Colon, J.; Liu, D.; Mao, M.; Norton, L.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration resistant prostate cancer

Meeting Abstract

Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Bilen, M. A.; Rosen, L. S.; Gottardis, M.; Infante, J. R.; Adams, B. J.; Liu, L.; Theuer, C. P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Pal, S. K.; McDermott, D. F.; Atkins, M. B.; Escudier, B.; Rini, B. I.; Motzer, R. J.; Fong, L.; Joseph, R. W.; Oudard, S.; Ravaud, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors

Meeting Abstract

Papadopoulos, K. P.; Autio, K. A.; Golan, T.; Dobrenkov, K.; Chartash, E.; Li, X. N.; Wnek, R.; Long, G. V.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Exercise trends among previously non-exercising breast cancer survivors: Analysis of an ethnically diverse sample

Meeting Abstract

Oza, S.; Blinder, V. S.; Tran, C.; Patil, S.; Gany, F.; Roberts, N.; Kampel, L. J.; Malik, M.; Bao, T.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC): Updated response and survival results

Meeting Abstract

O'Donnell, P. H.; Balar, A. V.; Vuky, J.; Castellano, D. E.; Bellmunt, J.; Powles, T.; Bajorin, D. F.; Grivas, P.; Hahn, N. M.; Plimack, E. R.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save